IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s):

Tachikawa et al.

Application No.: 10/550,324

Patent No.:

7,659,125

Filing Date:

September 23, 2005

Issue Date:

February 9, 2010

Docket No.:

2352.009

Title:

Latex Reagent for Adiponectin Analysis and Method of Adiponectin Analysis

To:

Attention: Certificate of Corrections Branch

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322 FOR PATENT OFFICE MISTAKE AND **UNDER 37 C.F.R. § 1.323 FOR APPLICANT'S MISTAKE**

Attention Certificate of Corrections Branch

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir/Madam:

Upon proofreading the sealed patent, the patentee noticed an error(s) in the printed patent due to a mistake by the patentee. In accordance with 35 U.S.C. § 255, patentee requests a Certificate of Correction.

This error occurred in good faith and correction of the same would not involve changes in the patent that would constitute new matter or would require reexamination.

Enclosed herewith is a proposed Certificate of Correction incorporating an amendment to correct the errors. Because the referenced error was due to applicant's own mistake, submitted herewith via EFS-Web using Deposit Account No. 08-1935 is payment of the fee required under 37 C.F.R. § 1.20(a) in the amount of \$100.

Respectfully submitted,

Kathy Smith Dias Attorney for Patentee

Registration No.: 41,707

May 24, 2010

HESLIN ROTHENBERG FARLEY & MESITI P.C.

5 Columbia Circle

Albany, New York 12203-5160 Telephone: (518) 452-5600

Facsimile: (518) 452-5579

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page <u>1</u> of <u>1</u>

PATENT NO.

7,659,125

APPLICATION NO.:

10/550,324

ISSUE DATE

February 9, 2010

INVENTOR

Tachikawa et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Assignee (73): insert -- Mitsubishi Kagaku Iatron, Inc., Tokyo, (JP) and Otsuka Pharmaceutical Co., Ltd., Tokyo (JP) --